BioPharmSignal logoBioPharmSignal

Biotech News

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

Rocket Pharmaceuticals (RCKT)Rocket PharmaceuticalsEarnings

PRV monetization provides $180 million in non-dilutive capital to support cardiovascular pipeline Cash runway extended into the second quarter of 2028 CRANBURY, N.J. --(BUSINESS WIRE)--Apr. 28, 2026-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology

Related news

RCKTRocket Pharmaceuticals2026-06-12 11:00 EST

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million

ARWRArrowhead Pharmaceuticals2026-08-04 20:01 EST

Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results

CRNXCrinetics Pharmaceuticals2026-08-03 20:05 EST

Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

ARWRArrowhead Pharmaceuticals2026-07-21 11:30 EST

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results

CRNXCrinetics Pharmaceuticals2026-06-30 20:05 EST

Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026

ZNTLZentalis2026-08-06 20:05 EST

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

RCKTRocket Pharmaceuticals2026-05-28 11:00 EST

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

VYGRVoyager Therapeutics2026-08-06 20:01 EST

Voyager Reports Second Quarter 2026 Financial and Operating Results

RIGLRigel Pharmaceuticals2026-08-04 20:01 EST

Rigel Reports Second Quarter 2026 Financial Results

TSHATaysha Gene Therapies2026-08-04 20:00 EST

Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11

View all latest news

Rocket Pharmaceuticals

Gene Therapies for Rare Disease Rocket Pharmaceuticals develops gene therapies for rare hematologic and cardiovascular disorders using lentiviral and adeno-associated-virus vectors. Commercial Hematology Franchise KRESLADI is an ex vivo lentiviral gene therapy approved for severe leukocyte adhesion deficiency type I. It represents...

Recent company news

RCKTRocket Pharmaceuticals2026-08-03 11:00 EST

Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease

RCKTRocket Pharmaceuticals2026-06-12 11:00 EST

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million

RCKTRocket Pharmaceuticals2026-05-28 11:00 EST

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

RCKTRocket Pharmaceuticals2026-05-07 20:00 EST

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

RCKTRocket Pharmaceuticals2026-04-28 11:00 EST

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

Stock data

Close
3.54 USD
Market cap
315.57M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States